Why you should be informed about NVC

NVC is the only FDA cleared treatment for Amblyopia with an abundance of a supporting clinical study and many peer reviewed articles were published on the subject.

Optometrists are in the front line of patients difficulties with Amblyopia.  NVC is the first treatment of its kind that allows an Optometrist to enhance their relationships with referring Ophthalmologists. By enlisting community physicians, an Optometrist can create a collaborative environment in which patients benefit from a non invasive vision correction technology while under the care of their primary occular physician.

A growing number of Ophthalmologists have realized the importance of NVC to their practice and have successfully treated their most challenging cases.

Occular Health Technicians and professionals should be aware of this technology and places where treatment is being offered. Contact MSO for more information about a treatment center near you.

How it Works

NVC Amblyopia treatment is computer-based, composed of a series of about 30-40 sessions. The computer-assisted part of the treatment is home-based. Along the treatment course, the patient should be monitored by a certified eye care provider. The eye care provider should perform a comprehensive screening examination in order to assist in establishing patient’s eligibility to the treatment. The patient should be prescribed with the optimal refractive correction for his/her amblyopic eye. Patient should use this prescribed eyewear from now on during treatment sessions and in all daily activities. Patient that received new eyewear prescription will undergo an adaptation period to the new eyewear (up to a week). Following the adaptation period, the eye care provider should ensure that the patient has adjusted to the new eyewear, and then perform the Baseline examination. After the Baseline examination, the computer-assisted part of the treatment begins. Patients should undergo visual acuity tests every 5 treatment sessions. These periodic VA tests will be used to determine whether the patient responses to the treatment, and later determine whether the visual improvement potential has been exhausted. Every 4 periodic VA tests, best refractive correction should be evaluated. If needed, new prescription should be given to the patient. Following the end-of-treatment decision, the patient should be scheduled for final examination, which is identical to the baseline examination. The patient should be scheduled for a follow up examination (identical to the baseline examination) every 6 months.

Highlights of the clinical results

The following results refer to the Clinical trials, of which results where submitted to the FDA. After careful examination by the FDA, NVC^TM was cleared for marketing.

The clinical trial included 44 patients in the treatment group, and 10 in a control group. The control patients have not improved their vision at all. Within the treatment group, the following results were observed:

• The success rate within the treatment group (44 patients) is 70.5% (31 out of 44 patients).
• 29.5% of the patients have not shown the full 2-lines of anticipated improvement.
• The average improvement among all 44 patients (including patients that did not show improvement) is 2.5 ETDRS lines. It is an average improvement of 83% in the visual acuity, compared to each baseline (an improvement of 3 lines in the visual acuity test is an improvement of 100%).
• Average improvement within the sub-group that was successfully treated (70% of the patients) is 3.1 lines, which is doubling of the visual acuity.
• Almost half of the successfully treated sub-group reached 20/25 vision or better, while 19% (6 patients) improved to 20/20 vision or better (“super-normal vision”).
• Among patients having a baseline VA of 20/50 and worse, 70% achieved a final VA of 20/40 and better.
• The contrast sensitivity function (CSF) of the treatment group improved remarkably and significantly. The CSF average – after treatment is within the normal range.
• Additional visual functions, i.e. binocular functions and reading abilities (near visual acuity), are significantly improved among the treatment group.
• The control group showed no improvement.
• There is no significant difference in improvement with relation to age.
• The visual acuity of all amblyopic categories (per diagnosis) is improved during treatment.
• Retention monitoring at 12 months show excellent results. These results meet the expectations of the science and treatment philosophy, and lead to the expectation that the results will be maintained for a long period of time.

The following chart depicts the progress of selected individuals’ visual acuity as a function of time/treatment sessions (visual acuity tests are done every four treatment sessions):

GRAPHS OF CLINICAL RESULTS

Visual acuity improvement and 3-months retention follow-up of each individual patient: each bar in the chart below represents the progress of an individual patient. The bars are sorted by the baseline visual acuity. The lower point is the starting visual acuity, the higher point is the acuity achieved in the end of the treatment.

The following chart shows retention follow-up every 3 months, up to 1 year:

Learn more by visiting our clinical pages.
 

HOME SITE MAP CONTACT US PRIVACY STATEMENT TERMS OF USE FEEDBACK

Copyright © 2003 Medical Service Options, Inc.. All rights reserved. 9-10 Saddle River Rd, Fair Lawn, NJ 07410 Tel: (201) 670-9999 Fax: (201) 670-0782

Site design, graphics, and clinical consulting: 6footmedia